Trends in the Concomitant Prescribing of Opioids and Benzodiazepines, 2002−2014

      Introduction

      Although many clinical guidelines caution against the combined use of opioids and benzodiazepines, overdose deaths and emergency department visits involving the co-ingestion of these drugs are increasing.

      Methods

      In this ecologic time series study, the IMS Health Total Patient Tracker was used to describe nationally projected trends of patients receiving opioids and benzodiazepines in the U.S. outpatient retail setting between January 2002 and December 2014. The IMS Health Data Extract Tool was used to examine trends in the concomitant prescribing of these two medication classes among 177 million individuals receiving opioids during this period. The annual proportion of opioid recipients who were prescribed benzodiazepines concomitantly was calculated and stratified by gender, age, duration of opioid use, immediate-release versus extended-release/long-acting opioids, and benzodiazepine molecule. The proportion of patients with concomitancy receiving opioids and benzodiazepines from the same prescriber was also analyzed. Analyses were conducted from April to June 2015.

      Results

      The nationally projected number of patients receiving opioids and benzodiazepines increased by 8% and 31%, respectively, from 2002 to 2014. During this period, the annual proportion of opioid recipients dispensed a benzodiazepine concomitantly increased from 6.8% to 9.6%, which corresponded to a relative increase of 41%. Approximately half of these patients received both prescriptions from the same prescriber on the same day. Concomitancy was more common in patients receiving opioids for ≥90 days, women, and the elderly.

      Conclusions

      Concomitant prescribing of opioids and benzodiazepines is increasing and may play a growing role in adverse patient outcomes related to these medications.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jones C.M.
        • Mack K.A.
        • Paulozzi L.J.
        Pharmaceutical overdose deaths, United States, 2010.
        JAMA. 2013; 309: 657-659https://doi.org/10.1001/jama.2013.272
        • Warner M.
        • Chen L.H.
        • Makuc D.M.
        • Anderson R.N.
        • Miniño A.M.
        Drug poisoning deaths in the United States, 1980−2008.
        NCHS Data Brief. 2011; 81: 1-8
        • Chen L.H.
        • Hedegaard H.
        • Warner M.
        Drug-poisoning deaths involving opioid analgesics: United States, 1999−2011.
        NCHS Data Brief. 2014; 166: 1-8
        • Warner M.
        • Chen L.H.
        • Makuc D.M.
        Increase in fatal poisonings involving opioid analgesics in the United Sates, 1999-2006.
        NCHS Data Brief. 2009; 22: 1-8
        • Paulozzi L.J.
        • Mack K.A.
        • Hockenberry J.M.
        Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines—United States, 2012.
        Morb Mortal Wkly Rep. 2014; 63: 563-568
        • Wolf B.C.
        • Lavezzi W.A.
        • Sullivan L.M.
        • Flannagan L.M.
        One hundred seventy two deaths involving the use of oxycodone in Palm Beach County.
        J Forensic Sci. 2005; 50: 192-195https://doi.org/10.1520/JFS2004194
        • Cone E.J.
        • Fant R.V.
        • Rohay J.M.
        • et al.
        Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases.
        J Anal Toxicol. 2003; 27: 57-67https://doi.org/10.1093/jat/27.2.57
        • Cone E.J.
        • Fant R.V.
        • Rohay J.M.
        • et al.
        Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions.
        J Anal Toxicol. 2004; 28: 217-225https://doi.org/10.1093/jat/28.4.217
        • Calcaterra S.
        • Glanz J.
        • Binswanger I.A.
        National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999−2009.
        Drug Alcohol Depend. 2013; 131: 263-270https://doi.org/10.1016/j.drugalcdep.2012.11.018
        • Jones C.M.
        • McAninch J.
        Nonmedical-use related emergency department visits and drug overdose deaths involving the combination of opioid analgesics and benzodiazepines in the United States, 2004−2011.
        Am J Prev Med. 2015; 49: 493-501https://doi.org/10.1016/j.amepre.2015.03.040
        • Jones J.D.
        • Mogali S.
        • Comer S.D.
        Polydrug abuse: a review of opioid and benzodiazepine combination use.
        Drug Alcohol Depend. 2012; 125: 8-18https://doi.org/10.1016/j.drugalcdep.2012.07.004
        • Compton W.M.
        • Volkow N.D.
        Abuse of prescription drugs and the risk of addiction.
        Drug Alcohol Depend. 2006; 83: S4-S7https://doi.org/10.1016/j.drugalcdep.2005.10.020
      1. Cai R, Crane E, Poneleit K, Paulozzi L. Emergency department visits involving nonmedical use of selected prescription drugs in the United States, 2004−2008. J Pain Palliat Care Pharmacother. 2010;24(3):293−297. http://dx.doi.org/10.3109/15360288.2010.503730.

        • Substance Abuse and Mental Health Services Administration
        The TEDS Report: Admissions Reporting Benzodiazepine and Narcotic Pain Reliever Abuse at Treatment Entry.
        Substance Abuse and Mental Health Services Administration, Rockville, MDDecember 13, 2012
        • Jann M.
        • Kennedy W.K.
        • Lopez G.
        Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics.
        J Pharm Pract. 2014; 27: 5-16https://doi.org/10.1177/0897190013515001
        • White J.M.
        • Irving R.J.
        Mechanisms of fatal opioid overdose.
        Addiction. 1999; 94: 961-972https://doi.org/10.1046/j.1360-0443.1999.9479612.x
        • Pattinson K.T.
        Opioids and the control of respiration.
        Br J Anaesth. 2008; 100: 747-758https://doi.org/10.1093/bja/aen094
        • Lee S.C.
        • Klein-Schwartz W.
        • Doyon S.
        • Welsh C.
        Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone.
        Drug Alcohol Depend. 2014; 138: 118-123https://doi.org/10.1016/j.drugalcdep.2014.02.014
        • Peirce G.L.
        • Smith M.J.
        • Abate M.A.
        • et al.
        Doctor and pharmacy shopping for controlled substances.
        Med Care. 2012; 50: 494-500https://doi.org/10.1097/MLR.0b013e31824ebd81
        • Park T.W.
        • Saitz R.
        • Ganoczy D.
        • Ilgen M.A.
        • Bohnert A.S.
        Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study.
        BMJ. 2015; 350: h2698https://doi.org/10.1136/bmj.h2698
      2. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. In press. Online September 2, 2015. http://dx.doi.org/10.1111/pme.12907.

        • Rolfs R.T.
        • Johnson E.
        • Williams N.J.
        • Sundwall D.N.
        Utah Department of H. Utah clinical guidelines on prescribing opioids for treatment of pain.
        J Pain Palliat Care Pharmacother. 2010; 24: 219-235https://doi.org/10.3109/15360288.2010.503265
      3. Washington Agency Medical Directors Group. Interagency guideline on opioid dosing for chronic noncancer pain. www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf. Published 2010. Accessed July 2, 2015.

        • Kahan M.
        • Wilson L.
        • Mailis-Gagnon A.
        • Srivastava A.
        • National Opioid Use Guideline Group
        Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations.
        Can Fam Physician. 2011; 57: 1269-1276
        • Paone D.
        • Dowell D.
        • Heller D.
        Preventing misuse of prescription opioid drugs.
        City Health Inform. 2011; 30: 23-30
        • Manchikanti L.
        • Abdi S.
        • Atluri S.
        • et al.
        American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2−guidance.
        Pain Physician. 2012; 15(3): S67-S116
        • American Geriatrics Society
        2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.
        J Am Geriatr Soc. 2012; 60: 616-631
        • Fick D.M.
        • Cooper J.W.
        • Wade W.E.
        • Waller J.L.
        • Maclean J.R.
        • Beers M.H.
        Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a U.S. consensus panel of experts.
        Arch Intern Med. 2003; 163: 2716-2724https://doi.org/10.1001/archinte.163.22.2716
        • McLeod P.J.
        • Huang A.R.
        • Tamblyn R.M.
        • Gayton D.C.
        Defining inappropriate practices in prescribing for elderly people: a national consensus panel.
        CMAJ. 1997; 156: 385-391
        • Maletta G.
        • Mattox K.M.
        • Dysken M.
        Guidelines for prescribing psychoactive drugs in the elderly: part 1.
        Geriatrics. 1991; 46: 40-47
        • American Psychiatric Association Task Force on Benzodiazepine Dependency
        Benzodiazepine Dependence, Toxicity, and Abuse. American Psychiatric Publishing, Arlington, VA1990
        • Gomes T.
        • Mamdani M.M.
        • Dhalla I.A.
        • et al.
        Opioid dose and drug-related mortality in patients with nonmalignant pain.
        Arch Intern Med. 2011; 171: 686-691https://doi.org/10.1001/archinternmed.2011.117
        • Lavin R.A.
        • Tao X.G.
        • Yuspeh L.
        • Bernacki E.J.
        Impact of the combined use of benzodiazepines and opioids on workers’ compensation claim cost.
        J Occup Environ Med. 2014; 56: 973-978https://doi.org/10.1097/JOM.0000000000000203
        • Park T.W.
        • Bohnert A.S.
        • Austin K.L.
        • Saitz R.
        • Pizer S.D.
        Regional variation in benzodiazepine prescribing for patients on opioid agonist therapy.
        Psychiatr Serv. 2014; 65: 4https://doi.org/10.1176/appi.ps.201300419
        • Mellbye A.
        • Svendsen K.
        • Borchgrevink P.C.
        • Skurtveit S.
        • Fredheim O.M.
        Concomitant medication among persistent opioid users with chronic non-malignant pain.
        Acta Anaesthesiol Scand. 2012; 56: 1267-1276https://doi.org/10.1111/j.1399-6576.2012.02766.x
        • Kao M.C.
        • Zheng P.
        • Mackey S.
        Trends in benzodiazepine prescription and co-prescription with opioids in the United States, 2002−2009.
        Pain Med. 2014; 15: 488
        • Pincus H.A.
        • Tanielian T.L.
        • Marcus S.C.
        • et al.
        Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties.
        JAMA. 1998; 279: 526-531https://doi.org/10.1001/jama.279.7.526
        • Stafford R.S.
        • MacDonald E.A.
        • Finkelstein S.N.
        National patterns of medication treatment for depression, 1987 to 2001.
        Prim Care Companion J Clin Psychiatry. 2001; 3: 232-235https://doi.org/10.4088/PCC.v03n0611
        • Cook J.M.
        • Marshall R.
        • Masci C.
        • Coyne J.C.
        Physicians’ perspectives on prescribing benzodiazepines for older adults: a qualitative study.
        J Gen Intern Med. 2007; 22: 303-307https://doi.org/10.1007/s11606-006-0021-3
        • Everitt H.
        • McDermott L.
        • Leydon G.
        • Yules H.
        • Baldwin D.
        • Little P.
        GPs’ management strategies for patients with insomnia: a survey and qualitative interview study.
        Br J Gen Pract. 2014; 64: e112-e119https://doi.org/10.3399/bjgp14X677176
        • Dunn K.M.
        • Saunders K.W.
        • Rutter C.M.
        • et al.
        Opioid prescriptions for chronic pain and overdose: a cohort study.
        Ann Intern Med. 2010; 152: 85-92https://doi.org/10.7326/0003-4819-152-2-201001190-00006
        • Paulozzi L.J.
        • Zhang K.
        • Jones C.M.
        • Mack K.A.
        Risk of adverse health outcomes with increasing duration and regularity of opioid therapy.
        J Am Board Fam Med. 2014; 27: 329-338https://doi.org/10.3122/jabfm.2014.03.130290
      4. Food and Drug Administration. Extended-release (ER) and long-acting (LA) opioid analgesics risk evaluation and mitigation strategy (REMS). www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290.pdf. Published December 2014. Accessed June 12, 2015.

        • Trescott C.E.
        • Beck R.M.
        • Seelig M.D.
        • Von Korff M.R.
        Group Health’s initiative to avert opioid misuse and overdose among patients with chronic noncancer pain.
        Health Aff (Millwood). 2011; 30: 1420-1424https://doi.org/10.1377/hlthaff.2011.0759
      5. U.S. Department of Veterans Affairs. VA initiative shows early promise in reducing use of opioids for chronic pain. www.va.gov/opa/pressrel/pressrelease.cfm?id=2529. Published February 25, 2014. Accessed June 30, 2015.

      6. CDC. Visits to physician offices, hospital outpatient departments, and hospital emergency departments, by age, sex, and race. www.cdc.gov/nchs/data/hus/2012/088.pdf. Published 2012. Accessed June 21, 2015.

      7. CDC. Persons with hospital stays in the past year, by selected characteristics: United States, selected years 1997−2012. www.cdc.gov/nchs/data/hus/2012/093.pdf. Published 2012. Accessed June 21, 2015.

      8. CDC. Expenses for health care and prescribed medicine, by selected population characteristics: United States, selected years 1987−2010. www.cdc.gov/nchs/data/hus/2014/046.pdf. Published 2014. Accessed June 30, 2015.

      9. CDC. Severe headaches or migraine, low back pain, and neck pain among adults aged 18 and over, by selected characteristics: United States, selected years 1997−2013. www.cdc.gov/nchs/data/hus/2012/093.pdf. Published 2012. Accessed June 21, 2015.

        • McLean C.P.
        • Asnaani A.
        • Litz B.T.
        • Hofmann S.G.
        Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness.
        J Psychiatr Res. 2011; 45: 1027-1235https://doi.org/10.1016/j.jpsychires.2011.03.006
        • Kessler R.C.
        • McGonagle K.A.
        • Zhao S.
        • et al.
        Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.
        Arch Gen Psychiatry. 1994; 51: 8-19https://doi.org/10.1001/archpsyc.1994.03950010008002
        • Olfson M.
        • King M.
        • Schoenbaum M.
        Benzodiazepine use in the United States.
        JAMA Psychiatry. 2015; 72: 136-142https://doi.org/10.1001/jamapsychiatry.2014.1763
        • Reuben D.B.
        • Alvanzo A.A.
        • Ashikaga T.
        • et al.
        National Institutes of Health Pathways to Prevention Workshop: the role of opioids in the treatment of chronic pain.
        Ann Intern Med. 2015; 162: 295-300https://doi.org/10.7326/M14-2775
        • Reisfield G.M.
        • Webster L.R.
        Benzodiazepines in long-term opioid therapy.
        Pain Med. 2013; 14: 1441-1446https://doi.org/10.1111/pme.12236
        • Khong T.P.
        de Vries F, Goldenberg JS, et al. Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States.
        Calcif Tissue Int. 2012; 91: 24-31https://doi.org/10.1007/s00223-012-9603-8
      10. Substance Abuse and Mental Health Services Administration. Emergency department visits involving nonmedical use of the anti-anxiety medication alprazolam. http://archive.samhsa.gov/data/2k14/DAWN153/sr153-alprazolam-2014.pdf. Published May 22, 2014. Accessed June 24, 2015.

        • Sansone R.A.
        • Sansone L.A.
        Doctor shopping: a phenomenon of many themes.
        Innov Clin Neurosci. 2012; 9: 42-46
        • Worley J.
        Prescription drug monitoring programs, a response to doctor shopping: purpose, effectiveness, and directions for future research.
        Issues Ment Health Nurs. 2012; 33: 319-328https://doi.org/10.3109/01612840.2011.654046
      11. Finklea K, Sacco LN, Bagalman E. Prescription drug monitoring programs. Congressional Research Service: Washington, DC. http://fas.org/sgp/crs/misc/R42593.pdf. Published March 24, 2014. Accessed June 30, 2015.

        • Katz N.
        • Panas L.
        • Kim M.
        • et al.
        Usefulness of prescription monitoring programs for surveillance—analysis of schedule II opioid prescription data in Massachusetts, 1996−2006.
        Pharmacoepidemiol Drug Saf. 2010; 19: 115-123https://doi.org/10.1002/pds.1878
        • Rutkow L.
        • Turner L.
        • Lucas E.
        • Hwang C.
        • Alexander G.C.
        Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access.
        Health Aff (Millwood). 2015; 34: 484-492https://doi.org/10.1377/hlthaff.2014.1085

      CHORUS Manuscript

      View Open Manuscript